BAM
TERN

Belpointe Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Belpointe Asset Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$1.18K – 3093
2023
Q1 		$1.18K Buy
+100
New +$956 ﹤0.01% 3444

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Belpointe Asset Management's TERN Position: Q2 2023 in Review

Belpointe Asset Management sold out of Terns Pharmaceuticals (TERN) in Q2 2023, closing a stake of 100 shares — an estimated $1.18K sold.

Belpointe Asset Management first reported a position in TERN in Q1 2023 and held it in 1 quarter. The position peaked at $1.18K in Q1 2023. 103 funds tracked by Wall St. Rank hold TERN as of Q2 2023.

  • Belpointe Asset Management reported no remaining Terns Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 100 Terns Pharmaceuticals shares in Q2 2023, an estimated $1.18K.
  • Belpointe Asset Management first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Terns Pharmaceuticals position peaked at $1.18K in Q1 2023.
  • 103 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.